• Je něco špatně v tomto záznamu ?

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development

F. Wang, RM. Kream, GB. Stefano,

. 2020 ; 26 (-) : e924700. [pub] 20200505

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023043

The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023043
003      
CZ-PrNML
005      
20201214125201.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.12659/MSM.924700 $2 doi
035    __
$a (PubMed)32366816
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wang, Fuzhou $u Group of Neuropharmacology and Neurophysiology, Division of Neuroscience, The Bonoi Academy of Science and Education, Chapel Hill, NC, USA. Institute for Translational Medicine on Molecular Function and Artificial Intelligence Imaging, Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, China (mainland).
245    13
$a An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development / $c F. Wang, RM. Kream, GB. Stefano,
520    9_
$a The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine.
650    12
$a Betacoronavirus $x imunologie $7 D000073640
650    _2
$a koronavirové infekce $x imunologie $x prevence a kontrola $7 D018352
650    _2
$a lidé $7 D006801
650    _2
$a pandemie $x prevence a kontrola $7 D058873
650    _2
$a virová pneumonie $x imunologie $x prevence a kontrola $7 D011024
650    _2
$a messenger RNA $x imunologie $7 D012333
650    _2
$a RNA virová $x imunologie $7 D012367
650    _2
$a glykoprotein S, koronavirus $x genetika $x imunologie $7 D064370
650    12
$a virové vakcíny $7 D014765
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kream, Richard M $u International Scientific Information, Inc., Melville, NY, USA.
700    1_
$a Stefano, George B $u International Scientific Information, Inc., Melville, NY, USA. Center for Cognitive and Molecular Neuroscience, First Faculty of Medicine Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00003251 $t Medical science monitor : international medical journal of experimental and clinical research $x 1643-3750 $g Roč. 26, č. - (2020), s. e924700
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32366816 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214125201 $b ABA008
999    __
$a ok $b bmc $g 1595362 $s 1113719
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 26 $c - $d e924700 $e 20200505 $i 1643-3750 $m Medical Science Monitor $n Med Sci Monit $x MED00003251
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace